Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

DOI PDF 被引用文献3件
  • Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy;
  • Gunnar Birgegard
    Department of Haematology, University Hospital, Uppsala, Sweden;
  • Guido Finazzi
    Division of Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy;
  • Martin Griesshammer
    Department of Hematology and Oncology, Johannes Wesling Medical Centre Minden, Academic Hospital of the University of Hannover, Minden, Germany;
  • Claire Harrison
    Department of Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom;
  • Hans Carl Hasselbalch
    Department of Hematology, L. Herlev Hospital, University of Copenhagen, Copenhagen, Denmark;
  • Jean-Jacques Kiladjian
    Assistance Publique-Hopitaux de Paris, Hopital Avicenne, Service d'Hematologie Clinique, Université Paris 13, Bobigny, France;
  • Eva Lengfelder
    Department of Medicine III, Faculty for Medicine Mannheim, University of Heidelberg, Heidelberg, Germany;
  • Mary Frances McMullin
    Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom;
  • Francesco Passamonti
    Division of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • John T. Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, United Kingdom;
  • Alessandro M. Vannucchi
    Unità Funzionale di Ematologia, Dipartimento di Area Critica Medico Chirurgica, Università degli Studi, Firenze, Italy; and
  • Tiziano Barbui
    Division of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy

説明

<jats:p>European experts were convened to develop a definition of response to treatment in polycythemia vera (PV) and essential thrombocythemia (ET). Clinicohematologic (CH), molecular, and histologic response categories were selected. In ET, CH complete response (CR) was: platelet count less than or equal to 400 × 109/L, no disease-related symptoms, normal spleen size, and white blood cell count less than or equal to 10 × 109/L. Platelet count less than or equal to 600 × 109/L or a decrease greater than 50% was partial response (PR). In PV, CH-CR was: hematocrit less than 45% without phlebotomy, platelet count less than or equal to 400 × 109/L, white blood cell count less than or equal to 10 × 109/L, and no disease-related symptoms. A hematocrit less than 45% without phlebotomy or response in 3 or more of the other criteria was defined as PR. In both ET and in PV, molecular CR was a reduction of any molecular abnormality to undetectable levels. Molecular PR was defined as a reduction more than or equal to 50% in patients with less than 50% mutant allele burden, or a reduction more than or equal to 25% in patients with more than 50% mutant allele burden. Bone marrow histologic response in ET was judged on megakaryocyte hyperplasia while on cellularity and reticulin fibrosis in PV. The combined use of these response definitions should help standardize the design and reporting of clinical studies.</jats:p>

収録刊行物

  • Blood

    Blood 113 (20), 4829-4833, 2009-05-14

    American Society of Hematology

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ